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Dear Editor,
Treatment refractoriness is an important and frequent problem
among individuals with schizophrenia, causing enormous
suffering and distress to patients and families.1,2 Although
psychosocial interventions are fundamental, antipsychotic
treatment is the mainstay of care for schizophrenia. However,
about 30% of the schizophrenic patients do not respond
adequately to adequate antipsychotic treatment.2 Treatment of
refractory schizophrenia criteria were established based on Kane’s
studies with clozapine and modified by the IPAP algorithm:3 1)
no period of good functioning in the previous 5 years; 2) prior
non-response to at least 2 antipsychotic drugs of two different
chemical classes for at least 4-6 weeks each at doses  400 mg
equivalents of chlorpromazine or 5 mg/day of risperidone; 3)
moderate to severe psychopathology, especially positive symptoms.
Several studies and metanalyses confirm clozapine’s superior
efficacy on treatment-refractory schizophrenia,2,3 and the
psychopharmachologic mechanisms involved in this superiority
are not clear yet.2,4 Clozapine is the best validated approach, but
there are several other interesting approaches being developed.5
Although  refractory schizophrenia represents a challenge to the
clinicians, it is often underdiagnosed and undertreated.
 We have performed a study investigating the detection of the
refractory schizophrenia cases in an academic outpatient clinic
(Schizophrenia Program - PROESQ). We have developed a
screening questionnaire describing the clinical characteristics,
previous treatments and possible causes of refractoriness, and
assessed 198 outpatients with diagnosis of schizophrenia and
schizoaffective disorder. All psychiatrists (n = 17) were asked to
point out their possibly refractory outpatients, based on four criteria
stated in the questionnaire: treatment non-responder, non-compliant,
clozapine user, and concomitant use of two or more antipsychotic
drugs. Seventy patients (35%) met criteria for treatment refractory
schizophrenia after extensive clinical chart review. Forty-seven
patients (67%) were males, mean age 36 y.o. (range 17-59), the
age of onset of schizophrenia was 22 y.o. (range 12-44), disease
duration 13.7 years (SD = 7.8), the number of psychiatric
hospitalizations was 1.8 (0 to 10, SD = 2.1), and 34.3% were
alcohol and/or drug abusers/dependents. The treatment-refractory
patients had used on average 4.6 (SD = 1.7) antipsychotic drugs,
however only 43% (15% of all patients) had used clozapine.
These results show a low rate of recognition and appropriate
treatment of refractory schizophrenia patients in an academic
service in Brazil. We presume that these rates are even lower in
other centers in Brazil, being a large proportion of the psychiatrists
tolerant to imperative residual symptoms and misdiagnosing
clinical refractoriness. Improvement on current psychiatric training
is necessary to educate clinicians to recognize treatment-refractory
schizophrenia and to manage the related clinical issues, such
as poor compliance to medication, alcohol and drug abuse/
dependence, and comorbid depression. To properly treat refractory
schizophrenia patients in the public sector in Brazil, the outpatient
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clinics specialized in severe mental illnesses, such as the Centers
for Psychosocial Attention - Centros de Atenção Psico-Social
(CAPS), need psychiatrists trained to prescribe clozapine and
manage potentially serious adverse effects (such as neutropenia,
seizures and arrhythmias) and the availability of medication and
hematological exams.
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Dear Editor,
It was with great interest that we read the manuscript by
Mendlowicz & Figueira about intergenerational transmission of
family violence, which is an important subject in times of
increasing social violence.1 Thus we would like to contribute to
such debate, approaching the genetic participation and its
interaction with environmental factors in the manifestation of
this phenomenon.
Until the 80’s, most researchers used to believe that abused
children were more susceptible to developing violent and antisocial
behaviors in the adulthood, showing the importance of
environmental components as risk factors for this type of behavior.
However, only in the 90’s some authors started to investigate the
participation of the genetic component as a susceptibility factor
for the development of violent and antisocial behaviors. According
to these authors, the development of violence would not only be
mediated by the environment, however would be the result of
the interaction between genetic and environmental factors. In
the last five years, some studies have demonstrated that parental
antisocial behavior prospectively predicts antisocial behavior in
abused children, and that this kind of behavior presents a genetic
inheritance. Antisocial violent parents are more likely to abuse
their children than parents without such behavior (environmental
risk for antisocial behavior in children) and also can transmit
increased genetic risk for the development of antisocial behavior.2
In addition, molecular genetic studies have investigated which
genes could be involved in the inheritance of antisocial violent
behavior, as well as the relation between environmental and
genetic factors. For example, Caspi et al. investigated a sample
of 1,037 children, with 8% of them presenting history of severe
maltreatment.3 Such maltreated children, in an interesting way,
more often carried the genotype of monoamine-oxidase type A
(MAO-A) gene promoter region, which confers low levels of
enzyme expression. Once carrying this low MAO-A activity
genotype, the children presented a bigger chance to develop
antisocial behavior. Thus, this functional polymorphism in MAO-
A gene promoter region could be a risk factor for impulsive
behaviors in these children. This could explain why they are
more likely to expose themselves to abuse situations, and once
abuse occurred, the presence of this polymorphism could
contribute to the development of future antisocial traits,2
demonstrating the interaction between gene-environment factors
for the development of antisocial behavior. Recent meta-analysis
has confirmed the association between maltreatment and
antisocial behavior in individuals that present the low-MAO-A
allele,4 suggesting that the MAO-A gene may influence the
response to environmental factors, and this biological process
may be initiated early in life.4 Foley et al., in a large
epidemiologic twin study, described that this low-MAO-A active
polymorphism was a risk factor for the development of antisocial
behavior only in the presence of stressful environmental events,
which isolated would not configure a risk factor for this type of
behavior.5 This finding confirms the importance of the interaction
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